Sagar Parikh, MD

Combinatorial Pharmacogenomic Testing Improves Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized, Controlled Trial

Objectives: The GUIDED trial demonstrated that combinatorial pharmacogenomic (PGx) testing significantly improved the rate of response (p=0.007) and remission (p=0.005) and approached sig...

John Greden , MD;

Anthony Rothschild , MD;

Michael Thase , MD;

Boadie Dunlop , MD;

Richard Shelton , MD;

Charles Conway , MD;

Lisa Brown , PhD;

Jennie Depatie , PhD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Matthew Macaluso , DO;

Krystal Brown , PhD;

Michael J. Crescenz ;

Michael Jablonski , PhD;

Charles DeBattista , MD;

Sagar Parikh , MD;

11/22/2019

Personalized Goal Attainment After a Switch to Vortioxetine in Adults With Major Depressive Disorder (MDD): Results of a Phase 4 Open-Label Clinical Trial

This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.

Anna Eramo , MD;

Sagar Parikh , MD;

Lisa Mucha , PhD;

Clement Francois , PhD;

Sara Sarkey , PhD;

03/01/2019

Using a Genetic Test (Combinatorial Pharmacogenomics)To Help Choose Patient-Specific Antidepressants for Depression: a Large, Blinded, Randomized Control Trial

Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...

Anthony Rothschild , MD;

Boadie Dunlop , MD;

Michael Thase , MD;

Charles Conway , MD;

Richard Shelton , MD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Francis Mondimore , MD;

Krystal Brown , PhD;

Matthew Macaluso , DO;

Michael Jablonski , PhD;

Alexa Gilbert , MSc, MBA;

Bryan Dechairo , PhD;

Lindsey Burns , MBA;

Charles DeBattista , MD;

Sagar Parikh , MD;

John Greden , MD;

03/01/2019

Validation of Goal Attainment Scaling for Depression: Initial Findings From an Open-label Study in Patients Switching to Vortioxetine

Goal attainment scaling (GAS) for evaluating individualized patient treatment goals and progress was adapted for MDD (GAS-D) in an open-label study in patients switching to vortioxetine (...

Maggie McCue , MS, RD;

Lambros Chrones , MD;

Anna Eramo , MD;

Mark Opler , PhD, MPH;

Andrea Norcini Pala , PhD;

Sagar Parikh , MD;

David Hellerstein , MD;

03/01/2019